To the Editor Trinder and colleagues1 conclude that LPA genetic risk score and measured lipoprotein(a) level provide comparable risk prediction for incident atherosclerotic cardiovascular disease (ASCVD) and provide improvement in risk discrimination beyond guideline-supported risk scores, which supports that lipoprotein(a) is a risk-enhancing factor.
Schrock CG. Clinical Utility of Lipoprotein(a) for Screening Does Not Determine Clinical Utility of Lipoprotein(a) for the Patient. JAMA Cardiol. 2021;6(9):1096–1097. doi:10.1001/jamacardio.2021.1592
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.